Amphastar Pharmaceuticals Pre-Paid Expenses 2012-2024 | AMPH

Amphastar Pharmaceuticals pre-paid expenses from 2012 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Amphastar Pharmaceuticals Annual Pre-Paid Expenses
(Millions of US $)
2023 $9
2022 $8
2021 $7
2020 $7
2019 $10
2018 $5
2017 $10
2016 $3
2015 $4
2014 $4
2013 $5
2012 $4
2011 $
2009 $
Amphastar Pharmaceuticals Quarterly Pre-Paid Expenses
(Millions of US $)
2024-09-30 $18
2024-06-30 $8
2024-03-31 $9
2023-12-31 $9
2023-09-30 $6
2023-06-30 $6
2023-03-31 $7
2022-12-31 $8
2022-09-30 $6
2022-06-30 $6
2022-03-31 $6
2021-12-31 $7
2021-09-30 $8
2021-06-30 $6
2021-03-31 $7
2020-12-31 $7
2020-09-30 $11
2020-06-30 $9
2020-03-31 $9
2019-12-31 $10
2019-09-30 $10
2019-06-30 $8
2019-03-31 $9
2018-12-31 $5
2018-09-30 $7
2018-06-30 $4
2018-03-31 $6
2017-12-31 $10
2017-09-30 $9
2017-06-30 $7
2017-03-31 $8
2016-12-31 $3
2016-09-30 $4
2016-06-30 $2
2016-03-31 $3
2015-12-31 $4
2015-09-30 $4
2015-06-30 $3
2015-03-31 $4
2014-12-31 $4
2014-09-30 $5
2014-06-30 $4
2014-03-31 $6
2013-12-31 $5
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $4
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.142B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00